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Abstract
Background: Tuberculous pericarditis (TBP) is associated with high morbidity and mortality, and is an important
treatable cause of heart failure in developing countries. Tuberculous aetiology of pericarditis is difficult to diagnose
promptly. The utility of the new quantitative PCR test (Xpert MTB/RIF) for the diagnosis of TBP is unknown. This
study sought to evaluate the diagnostic accuracy of the Xpert MTB/RIF test compared to pericardial adenosine
deaminase (ADA) and unstimulated interferon-gamma (uIFNγ) in suspected TBP.
Methods: From October 2009 through September 2012, 151 consecutive patients with suspected TBP were
enrolled at a single centre in Cape Town, South Africa. Mycobacterium tuberculosis culture and/or pericardial
histology served as the reference standard for definite TBP. Receiver-operating-characteristic curve analysis was used
for selection of ADA and uIFNγ cut-points.
Results: Of the participants, 49% (74/151) were classified as definite TBP, 33% (50/151) as probable TBP and 18%
(27/151) as non TBP. A total of 105 (74%) participants were human immunodeficiency virus (HIV) positive.
Xpert-MTB/RIF had a sensitivity and specificity (95% confidence interval (CI)) of 63.8% (52.4% to 75.1%) and 100%
(85.6% to 100%), respectively. Concentration of pericardial fluid by centrifugation and using standard sample
processing did not improve Xpert MTB/RIF accuracy. ADA (≥35 IU/L) and uIFNγ (≥44 pg/ml) both had a sensitivity
of 95.7% (88.1% to 98.5%) and a negative likelihood ratio of 0.05 (0.02 to 0.10). However, the specificity and positive
likelihood ratio of uIFNγ was higher than ADA (96.3% (81.7% to 99.3%) and 25.8 (3.6 to 183.4) versus 84% (65.4% to
93.6%) and 6.0 (3.7 to 9.8); P = 0.03) at an estimated background prevalence of TB of 30%. The sensitivity and
negative predictive value of both uIFNγ and ADA were higher than Xpert-MT/RIF (P < 0.001).
Conclusions: uIFNγ offers superior accuracy for the diagnosis of microbiologically confirmed TBP compared to the
ADA assay and the Xpert MTB/RIF test.
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Background
Tuberculosis (TB) is a global health priority [1]. In de-
veloping countries with dual human immunodeficiency
virus (HIV) and TB epidemics there continues to be
high TB-related mortality [2]. In immunosuppressed
patients, this high mortality can be largely attributed
to the increased burden of disseminated and severe
forms of extra-pulmonary TB, such as tuberculous
pericarditis (TBP) [3]. TBP carries a high case fatality
rate (17% to 40% over six months) [3] and accounts for
approximately 7% of hospital admissions for acute
heart failure in Africa [4]. Despite the burden of dis-
ease and associated high mortality, the diagnosis of
TBP remains problematic because of the lack of a sim-
ple, rapid, accessible and accurate diagnostic test [5].
TBP fluid is known to be paucibacillary with estimated
culture and microscope smear-based diagnostic accur-
acy of only approximately 50% and 5%, respectively [6].
A definitive diagnosis of TBP is, therefore, challenging
and often delayed [7]. Recent studies have indicated
that the rapid initiation of anti-TB treatment may re-
duce mortality, making the investigation of new, rapid
diagnostic tests for TBP essential [8].
The Xpert MTB/RIF assay is a new quantitative polymer-
ase chain reaction (PCR) test that has been introduced for
the rapid diagnosis of Mycobacterium tuberculosis (M. tb)
and rifampicin resistance, providing a result in less than
two hours [9]. Xpert MTB/RIF is endorsed by the World
Health Organization (WHO) for the diagnosis of pulmon-
ary TB using sputum samples [10]. Validation studies using
culture positive sputum samples from pulmonary TB
patients show a pooled sensitivity of 98% and 68% in
smear-positive and -negative cases, respectively, and an
overall pooled specificity of 98% [11]. Except for a few iso-
lated cases, there are no prospective studies of the diag-
nostic utility of Xpert MTB/RIF test in TBP [12,13].
By contrast, proof-of-principle studies have demonstrated
the potential utility of the novel biomarker, unstimulated
interferon gamma (uIFNγ) as a diagnostic tool in pericar-
dial and pleural fluid [14,15]. One study found that, when
using a diagnostic cut-point of 0.2 IU/ml, pericardial fluid
uIFNγ offered a 98% sensitivity and 100% specificity for the
diagnosis of TBP. Despite these promising early results, the
measurement of uIFNγ has not translated into routine
clinical practice partly because of the lack of validation
of the original observations [5].
Adenosine deaminase (ADA) level is the current locally
available surrogate measure that suggests M. tb infection.
The South African National Health Laboratory Service
(NHLS) reference ranges for normal ADA levels are: 0 to
15 U/L for serum, 0 to 30 U/L for pleural fluid and 0 to 9
U/L for cerebrospinal fluid. Locally available, yet unvalid-
ated data regarding ADA measurements in pericardial
fluid suggests an ADA cut-off value of 40 U/L resulted in
a test sensitivity, specificity, positive predictive value,
negative predictive value and diagnostic efficiency of
84%, 80%, 91%, 66%, and 83%, respectively [16].
The aim of this study was to assess the diagnostic utility
of the new Xpert MTB/RIF test compared to ADA and
uIFNγ assays in the diagnosis of TBP in a population
with a high burden of TB.
Methods
Study population
Between October 2009 and September 2012, consecutive
patients with suspected TBP referred to Groote Schuur
Hospital in Cape Town for enrolment in the Investigation
of Management of Pericarditis in Africa (IMPI Africa)
registry [17] were screened for inclusion in this diagnostic
study. Inclusion criteria were the presence of a large
pericardial effusion amenable to safe pericardiocentesis
(greater than 10 mm echo-free space around the heart
in diastole), age 18 years or older and the provision of
informed consent. Exclusion criteria were pregnancy,
anti-TB treatment initiation >1 week prior to pericardio-
centesis and refusal or inability to sign consent. Informed
consent was obtained from each patient prior to enrol-
ment in the registry and the study protocol conforms to
the ethical guidelines of the 2008 Declaration of Helsinki
as reflected in a priori approval by the human research
ethics committee of the University of Cape Town (HREC
REF402/2005) (additional data provided in Additional file 1).
Diagnostic sample collection and handling
A minimum of 60 ml of pericardial fluid (PF) was collected
for diagnostic testing by means of percutaneous pericardio-
centesis. PF was sent to the NHLS for measurement of
ADA and lactate dehydrogenase (LDH) levels, differential
cell counts and cytology, as well as routine TB diagnosis
consisting of concentrated fluorescence smear microscopy
and mycobacteria growth indicator tube (MGIT) liquid cul-
ture (MGIT 960, BD Diagnostics, Hunt Valley, MD, USA).
Drug susceptibility testing was performed on positive
culture isolates using the Genotype MDRTBplus assay
(Hain Lifescience, Nehren, Germany). In addition, PF sam-
ples were stored at −20°C, for later measurement of uIFNγ
levels and performance of the Xpert MTB/RIF assay. Investi-
gators performing Xpert MTB/RIF and uIFNγ were blinded
to clinical and routine TB diagnostic findings and categorisa-
tion (additional data provided in Additional file 1).
Xpert MTB/RIF assay
The Xpert MTB/RIF assay was performed on PF samples
using the manufacturer’s specifications for sputum samples
as previously described (Cepheid, Sunnyvale, CA, USA) [9].
Where possible, Xpert MTB/RIF was performed using both
1 ml of unconcentrated and unprocessed PF as well as
3 to 20 ml of centrifuged (3,000 g × 15 minutes) PF
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reconstituted to 1 ml with phosphate buffered saline
(PBS). The fourth generation Xpert MTB/RIF cartridge
was used. The cycle threshold value (CT-values) indi-
cates the cycle number at which the molecular probe
becomes detectable and is proportional to the amount
of TB-specific starting template. The average CT-value
for the five TB-specific molecular probes and for the
spore-related positive control (lyophilized Bacillus
atrophaeus subsp. globigii spores) (SPC) are used as
surrogate markers of bacillary load and PCR inhibition,
respectively. All Xpert MTB/RIF results were available
within two hours from the time of sample processing.
The limit of detection was determined in duplicate by
spiking 0, 50, 75, 100 and 150 H37Rv colony forming
units (CFU) to 1 ml aliquots of PF before dilution with
sample buffer and subsequent Xpert MTB/RIF analysis.
This experiment was repeated twice, thus providing
four replicates for each CFU concentration. Inhibition
was evaluated by comparing the PCR cycle-threshold
(CT) values of the SPC from unconcentrated and con-
centrated samples.
ADA assay
An adenosine deaminase assay (Diazyme, Poway, CA, USA,
[18]) was performed on 1 to 8 ml PF samples, collected in
serum tubes, according to the manufacturer’s specifications
by the National Health Laboratory Services, Groote Schuur,
Cape Town (NHLS GSH). Samples were either processed
immediately or stored (at 2 to 4°C) for processing within
24 hours.
The Diazyme ADA assay is based on the enzymatic
deamination of adenosine to inosine, which is converted
to hypoxanthine by purine nucleoside phosphorylase. The
reagent is used at 37°C ± 0.5°C, using an instrument that
is capable of reading absorbance accurately at 540 nm
to 550 nm. ADA activity was measured as units per litre
(U/L), where one unit of ADA is defined as the amount
of ADA that generates one micromole (μmol) of inosine
from adenosine per minute at 37°C.
uIFNγ assay
uIFNγ levels were measured in duplicate using supernatant
attained from 3 to 20 ml of thawed and centrifuged (3,000 g
for 15 minutes) PF using the InterGam Ultrasensitive Rapid
Immuno-suspension Assay (IRISA; Antrum Biotech, Cape
Town, South Africa; www.antrumbiotech.com; limit of
detection = 5 to 10 pg/ml) following the manufacturer’s
instructions and without antigen stimulation.
Diagnostic classification for analysis
All participants who were included had a large pericardial
effusion on echocardiography. Participants were cate-
gorised into the following diagnostic groups based on a
combination of pericardial and non-pericardial sample
culture results, histopathology of pericardial biopsy sam-
ples, basic PF characteristics, and the commencement of
TB treatment as follows: (i) Definite-TB: at least one
M. tb sample positive by liquid culture (either pericardial
or non-pericardial) and/or granulomatous inflammation
on pericardial tissue histology (that is, composite reference
standard); (ii) Probable-TB: not meeting the criteria for
definite-TB, but based on clinical suspicion (symptoms,
imaging, and preliminary fluid analysis) commenced em-
pirically on TB treatment in the absence of an alternative
diagnosis; (iii) Non-TB: no microbiological evidence of
M. tb and an alternative diagnosis is available.
Modelling clinical predictors using multiple imputation
A univariable analysis was used to determined basic clinical
predictors of definite TBP. Thereafter, a set of multivariable
clinical predictors was generated using logistic regression
modelling. Multiple imputation by chained equations was
used to impute missing data prior to model building [19].
Rounded ß-coefficients from the reduced model of signifi-
cant variables were used to generate scores to quantitate
relevant clinical predictors. Receiver operating characteristic
(ROC) curve analysis was performed and three cut-points
were selected for rule-in, Youden’s index (the optimal
mathematical balance between sensitivity and specificity)
[20] and rule-out value. Diagnostic accuracy, including
95% CIs, for each cut-point, was assessed. Performance
was also compared against a previously formulated clinical
prediction rule (Tygerberg TB Pericarditis Diagnostic
Index Score (TDIS) of ≥6) [6].
Statistical analysis
Sensitivity, specificity, positive (LR+) and negative (LR-)
likelihood ratios, and positive predictive values (PPV)
and negative predictive values (NPV) for all diagnostic
tests are presented with 95% CIs. Demographic, clinical
and microbiological characteristics of different groups were
compared using χ2 and Wilcoxon rank-sum tests as appro-
priate. Diagnostic sensitivity and specificity of individual
and/or combinations of tests were compared using the χ2
and Fisher’s exact tests as appropriate. The Spearman cor-
relation coefficient (Rs) was used to evaluate the association
between Xpert MTB/RIF-generated PCR cycle-threshold
(CT) values and liquid culture time-to-positivity. All statis-
tical tests were two sided at α = 0.05. STATA IC, version 10
(Stata Corp, College Station, TX, USA) was used for all stat-
istical analyses. The STARD criteria were used for analysis
and reporting of this study [21].
Results
Clinical characteristics
Figure 1 shows the study flow chart. Of the 175 pa-
tients screened, 24 patients were excluded due to having
pericardial effusions that were not amenable to safe
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pericardiocentesis (n = 16), missing information (n = 4),
absence of a pericardial effusion (n = 3) and prolonged
TB therapy (n = 1). Of the remaining 151 patients, 49.0%
(74/151), 33.1% (50/151) and 17.9% (27/151) were classi-
fied as definite-, probable- and non-TB, respectively. Only
1/74 definite-TB patients was PF smear-positive.
Tables 1A and B show the clinical characteristics of
patients with suspected TBP stratified by final diagnostic
group. Of these patients, 74% (105/151) were HIV-infected
with a median (interquartile range (IQR)) CD4 count
of 139 (81 to 249); 9/151 participants refused HIV testing
or had an unknown HIV status. Only 18% (18/98) of
HIV-infected patients were on anti-retroviral therapy
at enrolment. Non-TB participants were significantly older,
less likely to be HIV-infected, and more likely to have
severe shortness of breath despite significantly smaller
pericardial effusions than those with definite and probable
TB. In contrast, definite-TB and probable-TB patients had
similar clinical characteristics.
To compare diagnostic accuracy between diagnostic
tests and basic clinical predictors, given the demographic
and clinical differences, a multivariate logistic regression
model was developed to generate a quantitative estimate
for the predictive value of clinical findings. Additional file 1:
Table S1 in the online supplementary materials shows
the results of the univariate and multivariate analyses.
A set of the following basic clinical predictors: age ≤50 years,
HIV-infection and the presence of night sweats offered
the best predictive utility for TBP. Table 2 compares
the diagnostic accuracy measures for the previously reported
Tygerberg diagnostic index score ≥6 and the quantified
clinical predictors of this cohort, using both a ROC-
selected rule-in cut-point of >6.1 and Youden’s rule-out
cut-pointof >3.5.
Xpert MTB/RIF
Of the 151 patients who underwent pericardiocentesis,
9% (13/151) were not tested by the Xpert MTB/RIF assay
because of missing samples. The range of PF volume used
for a concentrated Xpert MTB/RIF was 3 to 20 ml.
Spiking experiments in PF demonstrated that the Xpert
MTB/RIF assay was detected in 100% of samples spiked
with ≥75 CFUs/ml of PF [see Additional file 1: Figure S1,
4/4 replicates detected for 75, 100 and 150 CFUs/ml].
Table 3 shows that, overall, when comparing matched
samples, the concentration of PF did not significantly in-
crease the number of positive Xpert MTB/RIF results
(1 ml unconcentrated: 41% (48/117) versus 20 ml concen-
trated 53% (62/117), P = 0.07). However, a higher number
of indeterminate Xpert MTB/RIF results occurred when
using concentrated versus unconcentrated (1 ml) PF sam-
ples (10.4% (14/134) versus 2.1% (3/138), P = 0.005). No
difference in the mean CT-value ± SD Xpert MTB/RIF
Spore (Bacillus globigii) positive control CT-values were
noted between concentrated versus unconcentrated PF
samples (26.7 ± 2.4 versus 26.4 ± 2.2, P = 0.4). No associ-
ation between Xpert MTB/RIF-generated CT-values and
PF liquid culture time-to-positivity (in days) was detected
(Rs = 0.199, P = 0.3, Figure 2).
Overall, the sensitivity (95% CI) of PF Xpert MTB/RIF
was 63.8% (52.4 to 75.1) (Table 2). The sensitivity was
higher in HIV-positive compared to HIV-negative patients
Figure 1 Screening, recruitment and diagnostic classification of patients with suspected tuberculous pericarditis. TB = tuberculosis;
uIFNγ = unstimulated interferon gamma; TDIS: Tygerberg diagnostic index score; PF: pericardial fluid. *Insufficient clinical or diagnostic data
acquired at baseline assessment.
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(74.6% (61.7 to 84.2) versus 21.4% (7.6 to 47.6), P <0.001; see
Additional file 1: Table S2), corresponding to higher bacillary
loads in the PFs of HIV-positive patients (median (IQR)
time-to-positivity (days) of liquid TB culture samples
HIV-positive: 21 (17 to 29) versus HIV-negative: 25 (12
to 38), P <0.001]. Sensitivity did not decrease significantly
when definite- and probable-TB patients were combined
(P = 0.09, see Additional file 1: Table S3). Overall, Xpert
MTB/RIF specificity (95% CI) was 100% (85.6 to 100) when
using the composite reference standard, but only 69.0%
(59.2 to 78.7) when the microbiological reference was used
(P <0.001, see Additional file 1: Table S4). All positive PF
Xpert MTB/RIF were rifampicin-sensitive giving a specifi-
city (95% CI) for rifampicin resistance of 100% (88 to 100).
Sensitivity could not be calculated.
uIFNγ and ADA
Of the 151 patients enrolled, 6.6% (10/151) and 5.9% (9/151)
were not subjected to uIFNγ and ADA assays, respectively.
The optimal cut-points for uIFNγ and ADA levels to maxi-
mise diagnostic accuracy were determined using the ROC-
curve shown in Figure 3. uIFNγ and ADA had similar areas
under the ROC-curve (AUROC uIFNγ: 0.96 versus AUROC
ADA: 0.91, P= 0.33). For uIFNγ, both the Youden’s index
(cut-point that correctly classifies the most number of
patients) and optimal rule-out cut-point was 44 pg/ml,
while for ADA the cut-point currently utilised in routine
clinical practice is >35 IU/l [22] compared to a ROC se-
lected optimal rule-in cut-point which is 107 IU/L. These
cut-points are used for the diagnostic accuracy analyses
presented in Table 2.
Table 1 Baseline demographic and clinical (A), echocardiographic and biochemical (B) characteristics of patients
referred with suspected TB pericarditis
A.
Baseline feature All study patients Definite-TB Probable-TB Non-TB
Number = 151 Number = 74 Number = 50 Number = 27
Demographics
Age (median, IQR) 34 (29 to 42) 33 (27 to 38)* 33 (28 to 37)* 52 (34 to 60) *P <0.001
Male (number, %) 93 (62) 48 (65) 32 (64) 13 (48)
HIV positive (number, %)a 105 (74) 59 (80)* 41 (82)* 5 (28) *P < 0.001
CD4 count (median, IQR)a 139 (81 to 249) 131 (70 to 206)* 153 (81 to 271)* 301 (229 to 424) *P = 0.04
ARV therapy (number/Number, %) 18/98 (18) 10/54 (19) 7/39 (18) 1/5(20)
Presenting clinical features
NYHA Class I – II (number/Number, %) 77/134 (58) 39/66 (59)* 35/47 (75)* 3/21 (14) *P < 0.001
NYHA Class III – IV (number/Number, %) 57/134 (41) 27/66 (41)* 12/47 (25)* 18/21 (86) *P < 0.001
Systolic blood pressure (mean, SD) (number = 145) 113 (17) 113 (17) 112 (16) 115 (22)
Diastolic blood pressure (mean, SD) (number = 145) 72 (14) 72 (15) 72 (13) 73 (14)
Heart rate (mean, SD) (number = 146) 111 (20) 114 (22) 108 (16) 111 (21)
Serum biochemical data
Haemoglobin g/dl (mean, SD) 9.6 (2.1) 9.4 (2.1)* 9.3 (1.7)* 10.9 (2.3) *P = 0.004
Creatinine, μmol/L (median, IQR) 73 (59 to 90) 72 (58 to 86) 77 (61 to 92) 72 (61 to 81)
Total WCC × 109/L (median, IQR) 6.5 (4.8 to 9.3) 6.5 (4.4 to 8.2)* 5.8 (4.8 to 7.2)* 10.5 (7.1 to 15.2) *P <0.001
B.
Echocardiographic features
Size of effusion (mm) (mean, SD) (number = 126) 36 (14) 36 (14)* 38 (13)* 29 (14) *P <0.001
Tamponade (number, %) (number = 141) 94 (67) 50 (72) 32 (64) 12 (55)
Routine pericardial fluid analyses
ADA IU/L (median, IQR) (number = 142) 51 (34 to 75) 59 (45 to 86)* 51 (34 to 77)* 17 (11 to 27) *P <0.001
Total protein g/L (median, IQR) (number = 148) 60 (52 to 68) 59 (53 to 68) 63 (56 to 68) 56 (48 to 62)
Lactate dehydrogenase (median, IQR) (number = 135) 1419 (867 to 2305) 1553 (999 to 2800)* 1093 (725 to 1613)* 884 (442 to 2305) *P = 0.02
Total PF WCC × 109/l (Median, IQR) (number = 136) 2.1 (1.1 to 3.3) 2.0 (1.2 to 3.0) 2.2 (1.2 to 2.9) 3.0 (0.7 to 8.9)
Lymphocyte predominance (number/Number, %)b 52/107(49) 29/56 (52)* 22/34 (65)* 1/17 (6) *P <0.001
aNine patients refused testing or had unknown HIV status, and four HIV-infected patients had no CD4 cell count data. bMultiple invalid results. *P values indicate
significant differences between patient groups. ADA, adenosine deaminase; ARV, anti-retroviral therapy; IQR, interquartile range; NYHA, New York Heart Association;
PF, pericardial fluid; SD, standard deviation; WCC, white cell count.
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Table 2 Diagnostic accuracy measures of Xpert MTB/RIF and the biomarkers uIFNγ and ADA using ROC-selected cut-points (definite-TB for sensitivity and
non-TB for specificity calculations)
Diagnostic testa Sensitivity
(95% CI) (n/N)c
Specificity
(95% CI) (n/N)c
Positive likelihood
ratio, LR + (95% CI)
Negative likelihood
ratio, LR- (95% CI)
Positive predictive
value, PPV (95% CI)
Negative predictive
value, NPV (95%CI)
Xpert MTB/RIF 63.8% (52.4 to 75.1) 100% (85.6 to 100) n/c 0.36 100% 86.6%
44/69* *1 *2 26/26 *4 *5 (0.33 to 0.39) (98.0 to 100) (84.0 to 88.7)
uIFNγ (Intergam) (Youden’s, rule-in
and rule-out cut-points: ≥44 pg/ml)c
95.7% (88.1 to 98.5) 96.3% (81.7 to 99.3) 25.8 0.045 91.7% 98.1%
67/70* *3 P <0.001 26/27*6 (3.6 to 184) (0.023 to 0.09) (88.1 to 94.3) (96.8 to 98.9)
ADA (rule-in cut-point: >107 IU/ml) 15.7% 96%
(9.0 to 26.0) (80.5 to 99.3) 3.93 0.88 62.7% 72.7%
11/70 24/25 (0.21 to 72.5) (0.85 to 0.91) (51.4 to 72.8) (69.7 to 75.4)
*1P <0.001
ADA (cut-point in current clinical
use: ≥35 IU/ml) [5]
95.7% 84%
(88.1 to 98.5) (65.4 to 93.6) 6.0 0.051 71.9% 97.9%
67/70 21/25 (3.7 to 9.8) (0.026 to 0.10) (67.3 to 76.1) (96.4 to 98.7)
*1 *3P < 0.001 *4P = 0.03
Tygerberg score ≥6 85.3% 77.3%
(75.9 to 81) (56.6 to 89.9) 3.75 0.19 61.7% 92.5%
58/68 17/22 (2.52 to 5.59) (0.15 to 0.24) (56.9 to 66.2) (90.0 to 94.3)
*2P = 0.004 *3P = 0.04 *5P = 0.01 *6P =0.04
Clinical predictors (rule-in cut-point: >6.1) 60.8% 96.3%
(49.4 to 71.1) (81.7 to 99.3) 16.4 0.41 87.6% 85.1%
45/74 26/27 (2.25 to 119.9) (0.38 to 0.44) (82.4 to 91.4) (82.5 to 87.5)
*3P <0.001
Clinical predictors (Youden’s and
rule-out cut-point: >3.5)b
91.9% 81.5% 4.96 0.10 68.0% 95.9%
(83.4 to 96.2) (63.3 to 91.8) (3.34 to 7.36) (0.07 to 0.14) (63.3 to 72.4) (94 to 97.2)
68/74 22/27
*2P <0.001 *5P = 0.02
Xpert MTB combined with uIFNγ
(with uIFNγ if Xpert MTB/RIF negative)
97.1% 100% n/c
(89.9 to 99.2) (86.7 to 100) 0.03 100% 98.8%
66/68 25/25 (0.01 to 0.08) (98.7 to 100) (97.7 to 99.4)
Xpert MTB combined with ADA
(with ADA if Xpert MTB/RIF negative)
98.4% 100% n/c 0.02 100% 99.3%
(91.7 to 99.7) (85.7 to 100) (0.002 to 0.11) (98.7 to 100) (98.4 to 99.7)
63/64 23/23
aDenominators other than 74 definite- and 27 non-TB patients indicate missing test results. Thus, 5/74 definite- and 1/27 non-TB patients did not have an Xpert MTB/RIF performed; 4/74 definite-TB did not have a uIFNγ
(QFT-kit) test performed and 4/74 definite- and 2/27 non-TB did not have an ADA level measurement. Diagnostic accuracy measures presented in this table are for Xpert MTB/RIF performed on 1 ml unconcentrated PF,
uIFNγ (both the QFT-kit and Intergam-kits) performed on the supernatants on 3 to 20 ml of centrifuged PF, and ADA performed on 1 to 8 ml of unprocessed PF.
bYouden’s index (the cut-point allowing the most correctly classified) and optimal ‘rule-out’ (the cut-point with the lowest LR-) cut-points for the uIFNγ (both the QFT-kit and Intergam-kits) were the same (QFT: 0.18 IU/l, Intergam:
44 pg/ml) respectively. cP-values compare diagnostic tests for the indicated diagnostic accuracy measure, for example, sensitivity (specific proportions compared indicated by * and corresponding number symbol).
ADA: adenosine deaminase; CI: confidence interval; n/c: not calculable as denominator equals zero; PF, pericardial fluid; uIFNγ: unstimulated interferon gamma. The reference standard was culture and/or
histopathology pathognomonic of TB†. TB prevalence = 30% used for predictive value estimates.
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The overall sensitivity (95% CI) of uIFNγ was 95.7%
(88.1 to 98.5), which was similar to ADA using the clinical
cut-point (Table 2). However, the specificity (95% CI) of
uIFNγ was 96.3% (81.7 to 99.3) versus only 84% (65.4 to
93.6) for ADA at the clinical cut-point (P = 0.1). Simi-
larly, although the sensitivity of the biomarkers uIFNγ and
ADA was similar for both HIV-positive and -negative pa-
tients, the specificity of ADA (clinical cut-point) was
lower in HIV-positive patients (P <0.001, Additional file 1:
Table S2).
Comparative diagnostic accuracy of routine and new
same-day diagnostic tools
We further interrogated the potential clinical utility of
routine (that is, ADA assay) and new same-day diagnostic
tools (that is, uIFNγ and Xpert MTB/RIF) by comparing
positive (LR+) and negative (LR-) likelihood ratios (Table 2)
and positive (PPV) and negative (NPV) predictive values at
different prevalence rates of TB (TB prevalence = 30% in
Table 2, TB prevalence of 10%, 30%, and 50% presented
in Additional file 1: Table S5). With 100% specificity, the
LR + and PPV (irrespective of TB prevalence) for Xpert
MTB/RIF was excellent, but sensitivity was suboptimal
compared to other biomarkers and clinical predictors
and thus LR- was only 0.49. Compared to ADA (clinical
cut-point 35 IU/ml) and clinical predictors, the biomarker
uIFNγ (cut-point 44 pg/ml) offers better rule-in utility
with higher sensitivity, LR+, and in high TB prevalence
settings (prevalence = 50%) a PPV of 96.9% (95.1 to 98.1)
[see Additional file 1: Table S5]. Both ADA (clinical
cut-point 35 IU/ml) and uIFNγ (cut-point 44 pg/ml)
with sensitivities >95% offer excellent rule-out utility with
low LR- and NPV just below 95% in high TB prevalence
settings (prevalence = 50%, Additional file 1: Table S5).
Xpert MTB/RIF in combination with pericardial
fluid biomarkers
Table 2 shows the diagnostic accuracy of using PF Xpert
MTB/RIF together with the biomarkers ADA and uIFNγ.
Performing a PF Xpert MTB/RIF followed by either ADA
or uIFNγ offered equivalent excellent diagnostic accuracy
with sensitivity and specificities >97%.
Discussion
The performance of the new WHO-endorsed, Xpert
MTB/RIF assay has recently been reported for some types
Table 3 Comparison of Xpert MTB/RIF assay test characteristics and diagnostic accuracy when using unconcentrated
and concentrated pericardial fluid samples
Pericardial fluid type Indeterminate rate (number/total
number of assays performed)
Internal positive controla
CT-value (median, IQR)
Xpert MTB/RIF positive tests in
definite and probable-TB patients
Unconcentrated (1 ml) 2.1% (0.3 to 4.6) 3/138 26.2 (25.1 to 27.4) 41.0% (32.1 to 49.9) 48/117
Concentrated/centrifuged pellet (20 ml) 10.4% (5.3 to 15.6) 14/134 26.2 (25.1 to 27.6) 52.9% (43.9 to 62.0) 62/117
P-valueb 0.005 0.9 0.07
A median of 20 ml of pericardial fluid was centrifuged at 3,000 × g for 15 minutes with the pellet re-suspended in sterile PBS, followed by Xpert MTB. aInternal
positive control: to evaluate potential PCR inhibition an unrelated fragment of fungal DNA (Bacillus globigii) is co-amplified in the reaction; bP-values compare
unconcentrated and concentrated pericardial fluid samples for particular Xpert. CI, confidence interval; IQR: Interquartile range; TB, tuberculosis,
Figure 2 Scatter plot correlating pericardial fluid Xpert MTB/RIF-generated cycle threshold (CT) values with pericardial fluid liquid
culture time-to-positivity (days).
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of extra-pulmonary TB such as TB lymphadenitis [23],
pleural TB [24], and TB meningitis [25]. However, there
are no comprehensive data about TBP to guide clinical
practice. Here we report on the first large comprehensive
study of Xpert MTB/RIF for the diagnosis of pericardial
TB [5,10]. It is also the first study to compare Xpert MTB/
RIF to several alternative diagnostic assays, including ADA
and IFN-γ, and to evaluate test performance outcomes in a
TB and HIV-endemic setting.
The key findings of our study are that: (1) uIFNγ offers
superior accuracy for the diagnosis of microbiologically
confirmed TBP compared to the new Xpert MTB/RIF
test and the established ADA assay; (2) PF Xpert MTB/RIF
could bacteriologically confirm a TB diagnosis (and allow
for drug susceptibility testing) in two thirds of patients with
suspected TBP; (3) PF uIFNγ offered better rule-in diagnos-
tic utility compared to ADA in current clinical use, while
both tests could rapidly rule-out TBP; (4) PF Xpert
MTB/RIF, when combined with either ADA or uIFNγ,
offers >97% sensitivity and specificity for TBP diagnosis;
and (5) concentration of PF samples prior to Xpert MTB/
RIF testing increased the number of ‘indeterminate’ tests
without significantly improving diagnostic yield.
Xpert MTB/RIF testing is undergoing phased imple-
mentation in a number of high burden settings for rou-
tine diagnosis of pulmonary TB [26,27]. There is limited
information on the diagnostic utility of the test in extra-
pulmonary cases of TB, and, in particular, Xpert MTB/
RIF performance has only been evaluated in a very small
number of PF samples [13]. Our study is the largest sys-
tematic evaluation to date, and the first to examine
Xpert MTB/RIF level of detection in PF and explore the
effects of concentrating larger volumes of PF on Xpert
MTB/RIF performance. Importantly, Xpert MTB/RIF test-
ing could microbiologically confirm TB and allow drug sus-
ceptibility testing in almost two thirds of culture-positive
cases, which is higher than in other body cavity fluids, in-
cluding pleural, non-sputum biological fluids such as urine,
and similar to performance in induced sputum specimens
[13,28,29]. Preliminary level of detection experiments sug-
gest that the Xpert MTB/RIF assay could reliably detect PF
samples spiked with ≥75 cfus/ml of H37Rv, which is lower
than the 131 cfu/ml limit of detection found in spiked spu-
tum samples [30]. Further studies with more replicates are
required to confirm this finding. However, the diagnostic
yield from PF was not improved by centrifugation of larger
volumes and concentration only increased the number of
‘indeterminate’ test results, although this was not the result
of an increase in PCR inhibition. The increased error rate
may have resulted from reaction failure secondary to large
amounts of pelleted blood and other inflammatory proteins
found in pericardial exudates. Methods to further digest
these proteins or the addition of a PCR-friendly blood lysis
buffer may help to decrease error rates [31,32]. Interest-
ingly, unlike in sputum and pleural samples, no correlation
was found between Xpert MTB/RIF-generated CT-values
and liquid culture time-to-positivity using PF [33]. How-
ever, the sensitivity of Xpert MTB/RIF was found to be sig-
nificantly higher in HIV-positive versus negative patients,
and this was due to the higher bacillary loads, as measure
by liquid culture time-to-positivity (TTP), found in the PF
of HIV-positive versus -negative TBP. This sensitivity differ-
ence may impact on the utility of Xpert MTB/RIF in low
HIV prevalence settings.
Proof-of-principle studies in TB pericarditis have dem-
onstrated the potential utility of using uIFNγ PF levels
for diagnosis of TB pericarditis [6,14,34]. Although it
can be easily measured, it is not routinely performed
due to its high cost and the kits only being available in a
96-well format, which would lead to a considerable wast-
age of unused wells [5,35]. However, the recent availabil-
ity of a low-cost assay (Intergam, Antrum Biotech, Cape
Figure 3 Comparison of receiver operator characteristics (ROC) curves for the pericardial fluid biomarkers unstimulated interferon
gamma (uIFN-gamma) and adenosine deaminase (ADA). AUROC, area under the receiver operator characteristics curve. The point sensitivity
versus specificity for the Xpert MTB/RIF is indicated on the graph as a solid black triangle.
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Town, South Africa) which is tested in this study may allow
for more widespread use of uIFNγ for the diagnosis of TBP
in clinical practice. In this study, using ROC-curve analysis,
we demonstrate an optimal cut-point of 44 pg/ml, and
show that with this cut-point of uIFNγ we could detect
almost all definite-TB cases (missing only three cases)
and incorrectly classified only one non-TB case.
Are the findings of this study generalisable to other
settings, and does either Xpert MTB/RIF or uIFNγ testing
potentially offer utility beyond existing same-day diagnostic
tools, such as smear microscopy, PF ADA measurements
and/or basic clinical information? In this study we compare
the utility of Xpert MTB/RIF, uIFNγ or ADA, alone or in
combination across different TB prevalence rates, focusing
on the diagnostic priorities of rapid rule-in and rule-out,
as well as bacteriologically confirmed diagnosis. In a high
prevalence setting (TB prevalence >30%), Xpert MTB/RIF
and uIFNγ outperforms ADA and basic clinical predictors
for rapid rule-in (highest LR + and PPV). However, both
ADA and uIFNγ offer equivalent rapid rule-out utility,
outperforming Xpert MTB/RIF and clinical predictors.
Combining Xpert MTB/RIF testing followed by ADA or
uIFNγ in Xpert-negative PF maximised both sensitivity
and specificity to >97% for TBP diagnosis. This may offer
the best diagnostic approach in high burden settings, es-
pecially where drug-susceptibility testing is desirable, but
the cost of a two test algorithm will remain a key consid-
eration in resource-poor conditions where TB is endemic.
Xpert MTB/RIF currently costs approximately US$20/test,
while ADA measurement is less than US$0.1/test. Intergam
kits are not currently commercially available so the cost is
unknown but likely to be only slightly more than smear mi-
croscopy. Prospective studies of the cost-effectiveness of
diagnostic options are needed before it can be considered
for clinical practice.
Our study had a number of important limitations. This
study did not optimise PF sample volumes or processing
beyond comparing two volumes and a simple centrifuga-
tion step thought applicable to resource-limited settings.
The use of different volumes or alternative processing
methods may have improved Xpert MTB/RIF sensitivity
and/or decreased the high indeterminate rate found. A
low number of replicates were performed in limit of
detection experiments and these findings should be
confirmed in further studies. The study was conducted
in a high TB and HIV burden setting, which may limit
the generalisability of the findings. Performance may
differ in a low TB burden setting and where HIV co-
infection rates and, hence, bacterial load, are lower,
such as Europe and the US. However, the use of diagnostic
accuracy measures that are less affected by prevalence,
such as LRs, and generating estimates across varying TB
prevalence rates helps to highlight potential performance
differences between low and high burden settings and,
hence, improve generalisability. Whilst this is the lar-
gest study that has comprehensively evaluated several
diagnostic strategies and tools in the same prospective
cohort, the sample size was limited in the non-TB
group. The small number of non-TB patients reflects
the high burden of infectious and HIV-related disease
in the South African environment [27]. Although the
use of a combined reference standard may introduce a
minor degree of selection bias, this consideration is
outweighed by the avoidance of misclassification bias
when using a culture only reference (data provided in
the online supplementary materials).
Conclusions
In conclusion, uIFNγ offers superior accuracy for the
diagnosis of microbiologically confirmed TBP compared
to the new Xpert MTB/RIF test and the established ADA
assay, performed using available Xpert MTB/RIF testing
protocols without fluid-specific optimisation beyond simple
centrifugation. These data suggest that the uIFNγ assay
may be the optimal first line test for the diagnosis of TB
pericarditis, and merits consideration for implementation
in clinical practice. Furthermore, PF Xpert MTB/RIF, when
combined with either ADA or uIFNγ, offers high sensitivity
and specificity for TBP diagnosis. Studies are needed to test
the utility and cost-effectiveness of a two-test strategy,
which may be preferred in HIV-positive patients where bio-
marker specificity may be reduced. Collectively, these data
suggest that a biomarker-oriented approach may be feasible
and accurate for the diagnosis of suspected TBP in a high
TB and HIV prevalence setting.
Additional file
Additional file 1: Table S1 Table S2-5 and Figure S1.
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